| Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium Y Wang, P Jain, FL Locke, MJ Maurer, MJ Frank, JL Munoz, S Dahiya, ... Journal of clinical oncology 41 (14), 2594-2606, 2023 | 71 | 2023 |
| Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study. AR Mato, C Timlin, C Ujjani, A Skarbnik, C Howlett, R Banerjee, ... British journal of haematology 181 (2), 2018 | 67 | 2018 |
| Occurrence and recall rates of fertility discussions with young breast cancer patients R Banerjee, E Tsiapali Supportive Care in Cancer 24, 163-171, 2016 | 42 | 2016 |
| The human alpha defensin HD5 neutralizes JC polyomavirus infection by reducing endoplasmic reticulum traffic and stabilizing the viral capsid SR Zins, CDS Nelson, MS Maginnis, R Banerjee, BA O'Hara, WJ Atwood Journal of virology 88 (2), 948-960, 2014 | 35 | 2014 |
| Next-generation implementation of chimeric antigen receptor T-cell therapy using digital health R Banerjee, N Shah, AP Dicker JCO clinical cancer informatics 5, 668-678, 2021 | 27 | 2021 |
| Financial toxicity in hematological malignancies: a systematic review E Ouchveridze, R Banerjee, A Desai, M Aziz, W Lee-Smith, H Mian, ... Blood cancer journal 12 (4), 74, 2022 | 26 | 2022 |
| Medical student awareness of and interest in clinical informatics R Banerjee, P George, C Priebe, E Alper Journal of the American Medical Informatics Association 22 (e1), e42-e47, 2015 | 26 | 2015 |
| Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma R Banerjee, J Marsal, CY Huang, M Lo, S Kambhampati, VE Kennedy, ... Transplantation and Cellular Therapy 27 (6), 477. e1-477. e7, 2021 | 24 | 2021 |
| Maximizing home time for persons with cancer R Banerjee, M George, A Gupta JCO Oncology Practice 17 (9), 513-516, 2021 | 21 | 2021 |
| Are observational, real-world studies suitable to make cancer treatment recommendations? R Banerjee, V Prasad JAMA Network Open 3 (7), e2012119-e2012119, 2020 | 21 | 2020 |
| Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis BK Ragon, MV Shah, A D’Souza, N Estrada-Merly, L Gowda, G George, ... Blood advances 7 (12), 2746-2757, 2023 | 20 | 2023 |
| Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation S Sidana, S Kumar, R Fraser, N Estrada-Merly, S Giralt, V Agrawal, ... Transplantation and cellular therapy 28 (2), 83. e1-83. e9, 2022 | 20 | 2022 |
| Lyme neuroborreliosis presenting with alexithymia and suicide attempts R Banerjee, JJ Liu, HM Minhas The Journal of clinical psychiatry 74 (10), 2374, 2013 | 15 | 2013 |
| Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma KR Reyes, CY Huang, M Lo, S Arora, A Chung, SW Wong, J Wolf, RL Olin, ... Transplantation and Cellular Therapy 29 (6), 350-355, 2023 | 14 | 2023 |
| The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond R Banerjee, AH Kelkar, AC Logan, NS Majhail, N Pemmaraju Current Hematologic Malignancy Reports, doi: 10.1007/s11899-021-00620-w, 2021 | 13 | 2021 |
| Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma R Banerjee, S Midha, AH Kelkar, A Goodman, V Prasad, GR Mohyuddin British Journal of Haematology 196 (5), 1274-1277, 2022 | 12 | 2022 |
| Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome R Banerjee, B Fakhri, N Shah Leukemia & Lymphoma 62 (11), 2600-2611, 2021 | 12 | 2021 |
| Driving distance and patient-reported outcomes in hematopoietic cell transplantation survivors R Banerjee, CY Jean, NS Majhail, HSL Jim, J Uberti, V Whalen, AW Loren, ... Biology of Blood and Marrow Transplantation 26 (11), 2132-2138, 2020 | 12 | 2020 |
| Clinical outcomes and salvage therapies in patients with relapsed/refractory multiple myeloma following progression on BCMA-targeted CAR-T therapy KR Reyes, YC Liu, CY Huang, R Banerjee, T Martin, N Shah, SW Wong, ... Blood 140 (Supplement 1), 617-619, 2022 | 10 | 2022 |
| Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis O Pasvolsky, M Yeshurun, R Fraser, N Estrada-Merly, U Rozovski, ... Bone marrow transplantation 57 (1), 31-37, 2022 | 10 | 2022 |
Chiung-Yu HuangUniversity of California, San Francisco在 ucsf.edu 的电子邮件经过验证
